Evidence map›Paper›PMID 34476734›Full record

ArticleInternational journal of hematology2022

Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan.

Masahiro Ieko, Kazumasa Ohmura, Sumiyoshi Naito, Mika Yoshida, Makoto Saito, Kazuki Kiyohara, Shinri Miyazima, Takahiro Maeta, Akihiro Ohtsu, Kenji Shimosegawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Masahiro IekoDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan. iekomNo2020@gmail.com.ORCID http://orcid.org/0000-0003-1854-4543
Kazumasa OhmuraDepartment of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Sumiyoshi NaitoDepartment of Clinical Laboratory, Health Sciences University of Hokkaido Hospital, Sapporo, Japan.
Mika YoshidaDental Clinic, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Makoto SaitoDepartment of Internal Medicine, Aiiku Hospital, Sapporo, Japan.
Kazuki KiyoharaDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan.
Shinri MiyazimaDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan.
Takahiro MaetaDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan.
Akihiro OhtsuDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan.
Kenji ShimosegawaDepartment of Hematology, Iwate Prefectural Chubu Hospital, 17-10, Murasakino, Kitakami, Iwate, 024-8507, Japan.
Nobuhiko TakahashiDepartment of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Akitada IchinoseDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
Chubu National Hospital · JPHealth Sciences University of Hokkaido · JPKisarazu Hospital · JPYamagata University · JP

Funding

The Ministry of Health Labour and Welfare (JP) H30-Intractable diseases (general)-015
6 · The paper itself

Abstract

Coagulation factor inhibitors (CFIs) sometimes cause fatal bleeding conditions. Determination of an inhibitor titer (INH-titer) using the Bethesda method is essential for diagnosing diseases associated with CFIs and examining the effects of immunosuppressive therapy. We reviewed 17 cases with CFIs (acquired hemophilia A, n = 11; FV inhibitor, n = 6) to examine the usefulness of determining quantities of an autoantibody to a coagulation factor (CF-IgG) by ELISA for diagnosis and therapeutic efficacy, as compared with INH-titer. One patient with an INH-titer and no evidence of CF-IgG was lupus anticoagulant (LA)-positive, and thus the positive INH-titer may have been a false positive caused by LA. Although INH-titer alone was insufficient to correctly identify patients with CFI, determination of CF-IgG appeared to be useful. In addition, even after INH-titer disappearance, hemorrhagic conditions recurred when CF-IgG was detected. These findings suggest that the presence of a clearance antibody against the coagulation factor might reduce the activity of that coagulation factor even after disappearance of the corresponding neutralizing antibody. Although the diagnosis and therapeutic efficacy can also be determined by INH-titer disappearance and improvement of corresponding coagulation factor activity, determination of CF-IgG by ELISA can improve the accuracy of these assessments.

Indexed as

AgedAged, 80 and overAutoantibodiesAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFactor VIIIFemaleHemophilia AHumansImmunoglobulin GJapanMaleMiddle AgedAutoantibodiesBiomarkersFactor VFactor VIIIImmunoglobulin GAcquired hemophilia ABethesda methodCoagulation factor antibody quantityELISAFactor V inhibitor

Identifiers

PMID34476734
OpenAlexW3197494239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.